Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Anheuser-Busch (BUD)
Consensus Price Target: $76.95 (25.3% implied return)
Born out of a complicated web of mergers and acquisitions, Anheuser-Busch InBev (NYSE: BUD) boasts a powerhouse beer portfolio of Budweiser, Stella Artois, Corona, and local favorites around the world.
Why Are We Wary of BUD?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 1.2% over the last three years was below our standards for the consumer staples sector
- Shrinking unit sales over the past two years show it’s struggled to move its products and had to rely on price increases
- Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
Anheuser-Busch is trading at $61.39 per share, or 5.7x forward EV-to-EBITDA. Read our free research report to see why you should think twice about including BUD in your portfolio.
Amphastar Pharmaceuticals (AMPH)
Consensus Price Target: $32.50 (34.1% implied return)
Founded in 1996 and known for its expertise in complex drug formulations, Amphastar Pharmaceuticals (NASDAQ: AMPH) develops and manufactures technically challenging injectable and inhalation medications, including both generic and proprietary pharmaceutical products.
Why Are We Hesitant About AMPH?
- Revenue base of $722.7 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Demand is forecasted to shrink as its estimated sales for the next 12 months are flat
At $24.24 per share, Amphastar Pharmaceuticals trades at 7.4x forward P/E. Dive into our free research report to see why there are better opportunities than AMPH.
One Stock to Watch:
Renasant (RNST)
Consensus Price Target: $42.29 (25.6% implied return)
Founded in 1904 during a time when the South was rebuilding its economy, Renasant (NYSE: RNST) is a regional bank holding company that offers banking, wealth management, insurance, and specialized lending services throughout the Southeast.
Why Do We Like RNST?
- Impressive 12.6% annual net interest income growth over the last five years indicates it’s winning market share this cycle
- Exciting net interest income outlook for the upcoming 12 months calls for 28% growth, an acceleration from its five-year trend
- Operating profits are forecasted to increase over the next year as it scales and becomes more productive
Renasant’s stock price of $33.68 implies a valuation ratio of 0.8x forward P/B. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.
High-Quality Stocks for All Market Conditions
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
